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Introduction
Prostate cancer was diagnosed in approximately 200,000 Americans and caused nearly 25,000 deaths last year. Excruciating bone pain, fractures and death caused by prostate cancer invariably result from metastases, the majority of which are osteoblastic and osteosclerotic metastases to bone. These pathological events are well established, yet there is still very little known about the molecular events involved in this deadly process. During embryonic development, bone morphogenetic proteins (BMPs) act as morphogens to determine cell fate and tissue differentiation, and can induce new bone formation when implanted subcutaneously into rats. BMPs function to recruit progenitor stem cells and initiate their growth and differentiation into bone in a sequence of events reminiscent of the steps seen both in bone formation during embryogenesis, and prostate cancer metastases to bone. BMP functions can be inhibited by antagonists such as Noggin or DAN. DAN is a protein which was originally isolated as a tumor suppressor and is a member of a family of secreted BMP antagonists which function by binding to BMPs and preventing their interactions with BMP receptors. The underlying hypothesis of this proposal is that BMP morphogen activity is involved with the osteoblastic and osteosclerotic pathology that is commonly associated with prostate cancer skeletal metastases. Inappropriately high BMP activity can be the result of a combination of several factors, including 1) elevated expression of BMPs by prostate cancer cells, 2) increased signal transduction by BMP receptors and Smads, and 3) decreased expression of BMP antagonists such as DAN or Noggin, and 4) further elevation of BMP expression through autocrine or paracrine loops resulting in a vicious cycle of elevated expression. The overall objective of this proposal was to understand BMP signaling in prostate cancer and metastases, with an initial focus on BMP6 and BMP-antagonist DAN. Induction DAN mRNA in LNCaP Progress: To detect the expression 1ev-cells after 96 hours els of BMP morphogens, TaqMan real-time 2 -quantitative RT-PCR assays were performed on total RNA isolated from five different human prostate cancer biopsies, and from theIK human prostate cancer cell lines LNCaP, DU-0 145, and PC-3. In cancer biopsies, we found that the most highly expressed member of the .. BMP family was BMP-6. Messenger RNAs for the other BMP family members were also detected using the highly sensitive RT-PCR _-2 technique, although at levels substantially lower= L than BMP-6. We also detected the expression of all BMPs tested in the three prostate -3.2 cancer cell lines, although the level of BMP expression in the cell lines did not necessarily match the average levels found in patient Control +BMP6
biopsies. 
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As a follow-up to this observation, we have
25-
tested the whether BMP-6 could alter the expression of other BMP antagonists, including Noggin, Chordin, Cerberus and Gremlin. We
15-
found that BMP-6 strongly induced expression of Noggin mRNA in a dose-dependent manner, as shown in figure 2. We tested for human Noggin protein along with a constant 0-6 -1 10 100 1000 1O0ng/ml of BMP-6, we were able to show a ng/ml BMP-6 dose-dependent inhibition of BMP-6 activity in DU-145 cell culture. We found that 3jig does not formally show a direct binding interaction between Noggin and BMP-6, it is the production of Noggin protein in DU-145
highly suggestive of such an interaction. Evicell lines in the presence and absence of BMPdence for this is that direct binding of Noggin 6 in the culture medium, and found detectable to closely-related BMP-7 was shown to be amounts of Noggin protein only when BMP-6 the mechanism of inhibition. was added to the culture medium. A western blot of human prostate cancer biopsy hoWe have shown that BMP-6 and Noggin mogenate showed that both BMP-6 and Nogare present in homogenized prostate biopsies gin are present at the protein level in the at the protein level, that BMP-6 will induce biopsy. These results are shown in figure 3 .
Noggin production in cells, and that Noggin can inhibit BMP-6 activity. To gain insight Having shown the up-regulation of Noggin of whether these proteins might be interactmRNA and Protein by BMP-6, we wanted ing with each other in the prostate tissue, we to address the question of whether Noggin performed immunohistochemistry to examine could result in the inhibition of BMP-6 acthe distribution of noggin in normal and cantivity. While Noggin had been shown to incerous human prostates. All prostate biopsies hibit BMP-2/4 and bind to BMP-7, at the reacted positively with the anti-Noggin antitime this work was being performed there was body. Staining in normal prostate was oblittle data available on the ability of Noggin served primarily in epithelial cells, with little to bind to BMP-6 or inhibit BMP-6 activity, or no staining in the stromal areas. In high grade cancers, Noggin protein was localized
To overcome these technical obstacles, we to areas dense with carcinoma cells. In samdecided that an inducible expression system ples with mixed areas of connective tissue and would be more appropriate, and decided on carcinoma, there was also little or no stainthe Tet-ON retroviral system manufactured ing in the connective tissue. The distribution by Clontech. In this system, cells are first of Noggin appears very similar to the distripermanently transfected with a Tetracycline bution of BMP-6 shown by others, indicating regulatory element. This element (rtTA) will the possibility of an interaction between these activate expression of cDNAs cloned downproteins in the prostate tissues.
stream of a Tetracycline Response Element The results from this specific aim have been (TRE) in the presence of Doxycycline, a synpublished in Cancer Research, Issue 64 pages thetic analog of tetracycline. In the absence 8276 through 8284, on November 15, 2004. of Doxycycline, transcription of the cDNA is highly repressed.
Specific Aim 2
We have succeeded in generating several subclones of the LNCaP and DU-145 prostate Goals: The goals of Specific Aim 2 were to cancer cell lines which permanently express generate sub-clones of LNCaP cell lines that the Tet-ON regulatory element. These cell over-express BMP6, and sub-clones that overlines are a valuable research tool, with the poexpress BMP antagonist DAN, by stable plastential to change not only the level of BMP-6 mid transfections. Additional goals were to or DAN that is produced, but also the time test the hypothesis that recombinant BMP-6 during which the protein is produced, simcan bind to recombinant DAN in vitro, and if ply by adding or removing varying amounts so, test the hypothesis that DAN can inhibit of Doxycycline. the BMP-6 bone-forming activity in vivo usUsing a luciferase reporter, we have quaning our established bio-assay.
tified the fold-induction and basal expression levels in these cells. There is a low basal level Progress: We cloned BMP-6 and DAN of luciferase expression even in the absence of cDNAs individually into the pcDNA6 mamDoxycycline. In the presence of nanogram to malian expression vector sold by Invitrogen, microgram amounts of Doxycycline, expresand then transform LNCaP or PC-3 prostate sion of the luciferase reporter increases in a cancer cells. The transformed cell populations dose-dependent manner to approximately 10 were placed under selective pressure with Blasto 50 times the basal level, depending on the ticidin for three weeks to eliminate untranscell line and the individual clone tested. We formed cells. This was accomplished. Howhave cloned the human Noggin cDNA into the ever, when the Blasticidin resistant cells (conappropriate vector for use in this system, and taining the pcDNA6 plasmid) were tested for are in the process of cloning DAN and BMP-6 the production either BMP-6 or DAN, we into this vector. We believe that the low basal were unable to detect increased levels of either expression in the absence of Doxycycline will protein. The pcDNA6 vector uses the constieliminate the selective pressures against the tutively strong CMV promotor to drive the continued over-expression of DAN or BMPexpression of the cloned cDNA. We believe 6 that we have observed using the pcDNA6 that there may be selective pressures against system, and therefore overcome the technical cells which constantly produce such unnatulimitations encountered. rally high amounts of BMP-6 or DAN proSince the last progress report, we have suctein, and therefore that the cells surviving the cessfully generated Du145 prostate cancer cell three week Blasticidin selection process have lines that express inducible amounts of Noglost the ability to express BMP-6 or DAN.
gin protein under control of the Doxycycline responsive TetON promotor, shown in Figure 4 . The basal level of gene expression in this protein production levels of BMP-6 need to be system is still relatively high even in the abassayed at the basal and doxycycline induced sence of Doxycycline induction. This is evlevels in both cell lines. ident from the immuno-reactive band in the We have demonstrated direct binding in-0/pg/ml lane of Figure 4 , which shows nogteractions in vitro of biotinylated recombinant gin protein being produced at detectable lev-DAN to BMP-6 and BMP-7, as well as transels without induction. Untransfected Du145 forming growth factor beta-2 (TGF-i32), as cells do not produce detectable levels of Nogshown in figure 5 . There was little or no bindgin protein using immuno-blot detection. Since we have shown the direct binding of BMP-6 and Noggin retrovirus were infec-DAN to BMP-6, the next task was to test ted into both LNCaP and Du145 cell lines, whether DAN could inhibit the activity of and antibiotic-resistant, infected cell popula-BMP-6. These experiments were to be done tions were obtained and frozen in liquid nifirst in cultures of prostate cancer cell lines, trogen for analysis. To date, we have characlater in an in vivo bio-assay. Unfortunately terized only the inducible Noggin producing the recombinant DAN that we were able to Du145 cells, as sown in Figure 4 and discussed produce in the pichia pastoris yeast expreson page 8. The complete characterization of sion system was not of sufficient quality for the inducible Noggin LNCaP, and inducible use in cell culture. We believe that non-protein BMP-6 cell sub-lines is in progress. At this contaminants in our preparations negatively point, stable integration of the inducible conaffected cell viability when DAN was added structs coding for antibiotic resistance alongto cell cultures in the amounts required to side BMP- 6 The negative selective pressure of BMP-6 affects the pathology of bone metastases of and DAN overexpression proved to be a setLNCaP cells, using cell lines generated above, back in the time-scale of this project, and Characterize their behavior with regards to necessitated the revised strategy for specific the kinetics of bone colonization, growth, and aims 2 and 3 discussed in the preceding parathe effects on surrounding bone. Identify the graph. However, there are great advantages BMP signaling pathways active in the injected to the inducible expression system. This incells (autocrine effect), and those active in the ducible system will allow us to control not bone surrounding the prostate cancer lesions only the level of BMP-6, noggin or DAN that (paracrine effects). Determine the androgen is produced, but also the time during which dependence of this metastasis model system, the proteins are produced, simply by adding or removing varying amounts of Doxycycline. Progress: We were somewhat delayed with these animal studies because of the unantic-
Additional Findings
ipated anti-proliferative effects of BMP-6 on the prostate cancer cell lines. We were unable
We were initially disappointed by the inabilto get stable cells that proliferate and also ity to clone stable cell lines with constitutive constitutively produce BMP-6, and therefore over-expression of BMP-6 as proposed in Speunable to use BMP overproducing cells the cific Aim 2. To investigate whether we may proposed animal model. We had to re-evaluate have introduced negative selective pressure or our strategy and decided to create cell lines other deleterious effects through constitutive that have a Tet-ON control element, which is expression of BMP-6, we examined the reused to drive expression of BMP-6 (or Nog- in Smad phosphorylation occurs with little or cells, using a luciferase reporter system. This no change in the total Smad protein within was accomplished in early 2004: we showed the time period studied. inducible expression of luciferase in both cell BMP-6 induces expression of p21 protein, types. The final step was to introduce retroa negative regulator of cell cycle progression. viral constructs coding for BMP-6, and B3MP
In many situations, p21 expression is depenantagonist DAN or Noggin into these cells. dent on signals from the p53 pathway. We show that p21 is up-regulated by BMP-6 in 15% of the top 100 "Cancer Signature Genes" both LNCaP and Du145 cells, which is nowere under control of BMP-6 in our simplitable because Du145 cells have a deficient p53 fled in vitro system. This provides further evpathway. We demonstrated that p21 is inidence of a causative role for BMP-6 in cancer duced by BMP-6 within 90 minutes and out to progression. at least 96 hours of continuous BMP-6 treatment.
Since p21 is a negative regulator of cell cycle progression induced by BMP-6, we studied the proliferation of LNCaP cells in the presence and absence of BMP-6. We showed that in serum-deprived conditions, BMP-6 is a negative regulator of cell growth, and that this growth inhibition is independent of androgens.
The negative regulation of cell growth by BMP-6 is one plausible explanation for the difficulties encountered in generating stable cells that constitutively over-express BMP-6, but there may be others.
To comprehensively examine other cellular responses to BMP-6, we performed microarray analysis of BMP-6 treated versus untreated Du145 cells. Affymetrix U133A 2.0 Plus genes were used, these chips have each over 47,000 individual probes representing all or most of the known human genes. This information was used to tabulate the expression of every protein known to be involved in BMP signaling, including all BMP family member, all extracellular antagonists, all intracellular signal-transduction molecules, and many more genes which had been reported to interact with the BMP pathway at some level. This significantly expands on the accomplishments of Specific Aim 1, and this work was included in the Cancer Research publication of 2004 included in the appendix 3.
The comprehensive list of BMP-6 response genes described above was generated from an in vitro treatment of prostate cancer cells with BMP-6. Since elevated BMP-6 expression correlates with worse cancer prognosis, we decided to cross-reference our BMP-6 response genes with "Cancer Signature Genes" identified by others (Febbo and Singh et al in Cancer Cell, 2002 as well as other public cancer gene databases). We found that a significant Key Accomplishments 
Conclusions
We have successfully completed the work proposed in specific aim 1 and 2, and are prepared to complete specific aim 3. The accrued knowledge of BMP signaling pathways, including receptors and native antagonists, and BMP-response genes, will help aid in the design of potential antagonists to block BMP signaling and reduce pain and pathologic fractures of bone in prostate cancer metastases. Tob, CBP/P300, and many more). It is the combined effect of this large symphony of BMP signaling molecules that will ultimately Prostate cancer was diagnosed in more than 220,000 Americans last determine cellular response to BMP. year, and nearly 30,000 Americans died of this disease. Excruciating BMP-6 expression is increased in prostate adenocarcinoma, and bone pain, fractures, and death caused by prostate cancer are invari-several studies have shown a correlation between elevated BMP-6 and ably the result of metastases, the majority of which are osteoblastic osteoblastic metastases (19) (20) (21) (22) (23) . At present, there is still much to be and osteosclerotic to bone (1-5). Whereas the pathological events are learned about the function of BMPs and their antagonists in prostate well established, the molecular events involved in prostate cancer cancers. In this study, we investigated the expression levels of BMPs, metastasis are only beginning to be understood. The bone morphoge-their antagonists, and molecules associated with BMP activity. In netic protein (BMP) family of proteins was originally identified by the particular, we investigated the expression of BMP-6 and the BMP ability of BMPs to induce new bone formation when implanted in antagonist noggin in prostate cancer cell lines, with special focus on ectopic subcutaneous sites in rats (6) (7) (8) . BMPs initiate new bone reciprocal feedback regulation and proliferation. formation by recruiting progenitor stem cells and initiating their growth and differentiation into bone in a sequence of events reminiscent of the steps seen in bone formation during embryogenesis (8) . MATERIALS AND METHODS BMPs are active at low concentrations (10-50 ng/ml), although the Cell Culture. DU-145 and LNCaP cells were purchased from American exact determination of BMP concentrations required to elicit a re-Type Culture Collection (Manassas, VA) and cultured in the recommended sponse in vivo is complicated by the fact that BMPs are often bound media (Invitrogen, Carlsbad, CA). Fetal bovine serum (FBS) and charcoalto the extracellular matrix rather than soluble. At the mRNA level, it stripped FBS were purchased from Hyclone (South Logan, UT). Cells were has been shown that expression of BMP-7, but not BMP-4, is andro-seeded in media supplemented with 10% FBS at a density of 200,000 cells per gen dependent in mouse (9) and human prostates (10).
well in 6-well dishes (approximately 20,000 cells/cm 2 ) and allowed to attach The profound effects that BMPs have on cell fate and determination overnight. The culture medium was replaced with media supplemented with necessitate a tight regulation of BMP activities. There are more than 1% charcoal-stripped FBS for 24 hours, and then BMP-6, BMP-7, noggin, and a dozen different human BMPs, each of which has its own subset of steroid hormones (in media supplemented with 1% charcoal-stripped FBS)
were added for the indicated times. Phenol red was not a component of any activities and unique expression patterns. This regulation can occur at meiusdRcobntnginwsaeersgftrmD.AisEndifferent levels of the BMP signaling cascade, either extracellularly, at mide Reg onbPharmaceuticas agrown, NY). BM . and BMPmides (Regeneron Pharmaceuticals, Tarrytown, NY). BMP-6 and BMP-7 were the cell membrane, or within the cell. A family of extracellular BMP generous gifts from Dr. T. K. Sampath (Creative Biomolecules, Hopkinton, MA). Unless noted, all other reagents were purchased from Invitrogen.
BMP-6 SIGNALING IN PROSTATE
TCAGATCC'TT; NogginProbe, ACCCAGACCCTATCTTTGACCCCAGG; tronic Northern expression data, when available, were taken from the Cancer GremlinFwd, GCAAAACCCAGCCGCTTA; GremlinRev, GGTrGATGATGenome Anatomy Project databases. 3 GGTGCGACTGT; GremlinProbe, CAGACCATCCACGAGGAAGGCTGC; CerberusFwd, ACCATGAGGAAGCTGAGGAGAA; CerberusRev, GCAGG-RESULTS GCTGGTGGCTACA; and CerberusProbe, AGATCTG1TTGTCGCAGTGC-CACACC. Real-time quantitative RT-PCR was done using a Sequence DeIt is the combined effect of the many BMP signaling and regulatory tector 7700 and the EZ-RT-PCR reagents from Applied Biosystems.
proteins that ultimately determines cellular response to the presence of Expression of each mRNA was normalized to that of glyceraldehyde-3-exogenous BMP. We decided on a simple experimental model conphosphate dehydrogenase, and the fold change was calculated using the for-sisting of DU-145 prostate cancer cells cultured in the presence or mula 2'Ac' as described by Applied Biosystems. Each RT-PCR was done in absence of exogenously added BMP-6. We used thss model to detertriplicate, and the results shown are representative of at least two repeated mine which of the BMP signaling genes were (a) present in the cells experiments.
Western Blotting. Human prostate cancer biopsies were obtained from Dr. and (b) affected by the addition of BMP-6. Microarray experiments Ralph de Vere White (Department of Urology, University of California Davis were performed with RNA harvested from BMP-6-treated and conMedical Center) and homogenized in reducing SDS-PAGE sample loading trol DU-145 cells. These experiments confirmed the presence of buffer that contained 8 mol/L urea. After centrifugation for 5 minutes at BMP-6 mRNA, as well as the presence of the type I and type II BMP 12,000 X g, the supernatants were boiled for 5 minutes and then electrophorereceptors and Smads required for BMP signal transduction. The sed on precast 4-12% gradient gels (Invitrogen). Cultures of 200,000 cells various components of the BMP signaling system expressed by DUwere lysed in 100 to l of I x SDS-PAGE sample buffer, and 40 Al were loaded 145 cells are presented in Table 1 .
into each lane of a SDS-PAGE precast cell (corresponding to 80,000 cells per We next extended these findings beyond the culture model and lane for even protein loading), which was then processed as described above, asked which of these BMP signaling genes are present in prostate After transfer to Immobilon-P (Millipore, Bedford, MA), the membranes were using publicly available cancer microarrays and serial analysis of gene blocked with 2% bovine serum albumin and then incubated with the antiexpression (SAGE) data (Table 1 ). In the genes detected, there is noggin (Regeneron Pharmaceuticals) and anti-BMP-6 antibodies at 2 to 10 considerable agreement between the prostate biopsies and the DU-145 /Ag/ml and anti-p21 (BD Biosciences, San Jose, CA) and anti-phospho-Smad cell line. However, comparison of extended BMP family and related (Cell Signaling, Beverly, MA) at the dilutions recommended by the manufacsignaling molecules showed that many genes that were present in the turers. Detection was done by either horseradish peroxidase-conjugated goat DU-145 cell line were not detectable in RNA from the prostate antirabbit secondary antibodies and enhanced chemiluminescence (ECL; Amersham Biosciences, Piscataway, NJ) or alkaline phosphatase-conjugated goat antibodies and Enhanced ChemiFluorescence and quantified on a Storm-860
We were particularly interested in the genes that negatively regulate scanner (Amersham Biosciences). BMP signaling because elevated BMP-6 expression correlated with Immunohistochemistry. A slide array of 80 characterized, paraffinbone metastasis of prostate cancer. Noggin, Smad-6, Smad-7, and embedded 2-mm human prostate biopsies (lmgenex, San Diego, CA) was BAMBI are negative regulators of BMP signaling whose expression characterized by Imgenex using the Gleason grading scale. The slide array was was increased on BMP-6 treatment of DU-145 cells. BAMBI was also incubated with 25 j.sg/ml mouse anti-noggin monoclonal antibody using the up-regulated in cancerous prostates. The regulation of noggin by VectaStain ABC-AP kit according to the manufacturer's protocols (Vector BMP-6 will be presented in greater detail below. Laboratories, Burlingame, CA).
BMP-6 and Noggin Are Present in Prostate. To confirm the Cell Proliferation Assay. Cells were seeded in media supplemented with presence of BMP-6 and noggin in prostate at the protein level, 10% FBS at a density of 1.5 X I0W cells per well in 6-well dishes and allowed immunoblots of prostate cancer homogenate were probed with antito attach overnight. The culture medium was replaced with media supplebodies against human BMP-6 and noggin. Both of these proteins were mented with 10% charcoal-stripped FBS for 24 hours, and then BMP-6 and expressed in the homogenized prostate cancer biopsies (Fig. IA , dihydrotestosterone [DHT (in media supplemented with 10% charcoal-stripped Lanes I and 2, respectively).
FBS)] were added for a period of 7 days. Media were replaced and suppleImmunohistochemistry was used to examine the distribution of mented with BMP-6 and DHT every 2 to 3 days. Cells were lysed by the noggin in normal and cancerous human prostates. All prostate biopaddition of 500 jdl 0.5% SDS solution, and DNA was isolated using the phenol/chloroform method. The relative DNA concentration was obtained sies reacted positively with the anti-noggin antibody, and 2 ) and allowed to attach overnight. The culture medium was connective tissue and carcinoma, noggin was localized to the carcireplaced with media supplemented with 1% charcoal-stripped FBS for 24 noma cells, and there was little or no staining in the connective tissue. hours, and then BMP-6 was added in media supplemented with 1% charcoalUsing this technique, we were not able to demonstrate a difference in stripped FBS. DNA-free total RNA was prepared using RNEasy mini-colnoggin staining intensity among normal epithelium and low-grade and umns, using the on-column DNase digestion step. RNA samples were prohigh-grade cancer cells. cessed for analysis on Affymetrix U133 2.0 Plus arrays by the Gene BMP-6 Induces Noggin Expression. Recombinant human BMP-6 Expression Resource core facility at University of California Davis Medical protein added to cultures of DU-145 and LNCaP prostate cancer cell Center. These arrays cover the entire human genome and include more than lines for 48 hours resulted in a dose-dependent increase in noggin 47,000 gene transcripts.
mRNA, as shown in Fig. 2A . This confirms the previous observations Public Databases. Twenty-seven normal and 52 cancerous prostate sam-made in rat osteoblasts (25) that noggin can be induced by BMP-6 in pies were processed on Affymetrix U95A microarrays by Singh et al. (24) , and the data were made publicly available.' We analyzed these files with dChip 1.32 to determine the presence or absence of each gene listed and whether there BMP antagonists, gremlin and cerberus, were examined in the same was differential regulation in tumor versus normal biopsies. SAGE and elecsamples and showed no significant changes in the presence of BMP-6 protein (Fig. 2C) . In LNCaP prostate cancer cell culture, the BMP- 6-induced increase of noggin mRNA was not dependent on the ray data showing that BMP-6 activates several negative feedback presence of androgens (data not shown). The induction of noggin mechanisms when added to DU-145 cell culture. Inhibitory Smad-6 mRNA was observed in both the LNCaP (androgen receptor-positive) and Smad-7 are up-regulated and function to block BMP signal and DU-145 (androgen receptor-negative) cell lines, providing further transduction by interfering with the activation of receptor Smads evidence that this is an androgen-independent event ( Fig. 2A) .
(Smads 1, 5, and 8; ref. 26) . Smurf-2 is up-regulated by BMP-6 and The increased noggin production on BMP-6 treatment was also functions by increasing the degradation rate of receptor Smads, thus confirmed at the protein level. The addition of 100 ng/ml BMP-6 to attenuating BMP signaling (27). BAMBI was up-regulated by BMP-6 DU-145 cell culture for 48 hours resulted in the expression of detect-and acts as a kinase-deficient type I receptor unable to activate Smads able amounts of noggin in the cells, whereas noggin protein was not (18) . These proteins are examples of negative feedback regulation that detectable in cells cultured in the absence of BMP-6 (Fig. IA, Lanes reduce or weaken BMP signaling. 3 and 4). Noggin protein was detected in the cells and their associated
However, a few regulatory proteins were affected by BMP-6 that extracellular matrix, but not in the cell culture supernatant.
further activate the BMP signaling pathway. SIP-l, a Smad-binding Noggin Inhibits BMP-6 Activity. Having shown that BMP-6 re-protein and transcriptional repressor of E-cadherin, was down-reguproducibly up-regulates noggin at the mRNA and protein levels, we lated by BMP-6. E-cadherin has been proposed as a tumor suppressor designed experiments to determine whether noggin could act as an gene, and its expression is frequently decreased in prostate cancers. antagonist to BMP-6. Previously, it had been shown that noggin SNIP-1 was also down-regulated by BMP-6 treatment and has been inhibits the activity of BMP-2, -4, and -7, but the effect of noggin on shown to suppress the transforming growth factorp signaling pathway BMP-6 had not been demonstrated. Increasing amounts of noggin (28) . were added to cells cultured in the presence of 100 ng/ml BMP-6 for Again, we wanted to extend these findings beyond the DU-145 cell 48 hours, and quantitative RT-PCR was used to measure the up-culture model and ask which of these BMP signaling genes are regulation of noggin mRNA. Noggin protein at higher doses (1-3 involved in prostate cancer. To a large extent, the DU-145 cancer cell g.g/ml) reduced BMP-6 activity by 50% to 100% in both LNCaP and model system agrees with both the SAGE and cancer versus normal DU-145 cells. As a control, in the absence of BMP-6 protein, noggin prostate microarray data, although the data from the DU-145 cell protein had no discernible effect (Fig. 2C) .
arrays (Affymetrix 133 2.0 Plus chips) are much more complete than BMP-6 Activates Negative Feedback Mechanisms. Because el-the chips used by Singh et al. (24) (Affymetrix U95A chips) and also evated BMP-6 expression in prostate correlates with poor patient more sensitive than the SAGE technology. The cancer versus normal prognosis, we were interested in studying the expression of negative prostate comparisons reveal information about BMP regulation beregulators of BMP activity. As described above, the profound effects yond what is possible with DU-145 cell culture microarrays. For of BMPs on cells and tissues have given rise to many levels of example, DAN, an extracellular BMP antagonist protein, was downmechanisms to regulate these effects, including negative feedback regulated in prostate cancers compared with normal prostate both on loops that are activated by BMP-6. Table 2 is a summary of microar-microarray and SAGE data sets and was present but not affected by BMP-6 in DU-145 cell culture. These comparisons are presented in between elevated BMP-6 expression and tumor metastases, we Table 2 . wanted to (a) examine the BMP-6 signal transduction pathway, (b) In summary, we have demonstrated that BMP-6 induces noggin identify some of the downstream targets, and (c) characterize the expression in prostate cancer cell culture at the mRNA and protein effects of BMP-6 on the biology of prostate cancer cells. levels. Recombinant noggin protein inhibits this activity of BMP-6 in
The first few steps in BMP signal transduction involve binding of a prostate cancer cell culture system. In addition to noggin, BMP-6 BMP to its receptors, which are activated and subsequently phosphoactivates several other negative (and some positive) feedback mech-rylate Smads. These pathways are often disrupted in cancer cells (29) . anisms that may attenuate BMP signal transduction. The cancer cell To test whether Smads are phosphorylated on BMP-6 treatment of model data are in agreement with data derived from comparing DU-145 and LNCaP cells, immunoblots were performed on cell normal and cancerous prostate.
lysates and probed with antibodies that specifically recognize only BMP-6 Induces Smad Phosphorylation. Many studies have doc-phosphorylated Smad-1, -5, and -8. BMP-6 treatment induced Smad umented the function of BMPs in the context of bone development phosphorylation within 30 minutes, and elevated levels of phosphoand embryogenesis. However, the function of BMP-6 in the adult rylated Smads continued to be detected to at least 96 hours of BMP-6 prostate remains unknown. To extend the documented correlation treatment, as shown in ng/ml BP-6 pg/ml Noggin added to DU-145 cells for 48 hours in the presence of 100 ng/ml BMP-6 and 100 ng/ml DHT. BMP-6 activity untreated cells cultured for the same length of time under otherwise itors p21/CIP, p18, and p19 were up-regulated, and cyclin-dependent identical conditions. The amount of unphosphorylated Smad-1 protein kinases were down-regulated. remained essentially identical between BMP-6-treated and control BMP-6 Induces Expression of Id Proteins. Id proteins are inhibcells. Thus, the Smad phosphorylation pathway is intact in these cells itors of basic helix-loop-helix transcription factors that are under the and used for BMP signal transduction in response to exogenous control of BMP pathways in other cell types (32) and have been BMP-6.
identified as markers of prostate cancer progression (33-35). We BMP-6 Inhibits Cell Proliferation. Although microarray analysis found that BMP-6 dramatically increased the expression of Id-1, Id-2, has provided insight into how cells respond to BMP-6 at the molecular and Id-3 in the microarray, as shown in Table 3 . level, the response at the cellular level is still unknown. One component of malignant prostate cancer is uncontrolled growth, and another DISCUSSION component is androgen independence. Experiments were performed to determine whether BMP-6 affects the proliferation rate of andro-
The misregulation of BMP and BMP signaling pathways in prostate gen-dependent LNCaP cells. BMP-6 inhibited LNCaP cell prolifera-cancer is becoming increasingly apparent. BMP-6 was studied in this tion after 1 week of cell culture in media supplemented with 10% report due to the demonstrated correlation of increased prostatic charcoal-stripped (androgen-free) serum, as shown in Fig. 2D . Two BMP-6 expression and cancer severity. However, recent publications lines of evidence indicated that this growth-inhibitory effect is not also show reduced expression of BMP-2 and Smads 4 and 8 in dependent on the presence of androgens. First, the effect was seen prostate cancers (29), and one report shows that BMP-5 is up-reguwith or without addition of DHT to the medium. Second, the growth-lated in benign prostatic hyperplasia (36). inhibitory effect of BMP-6 was also seen in androgen-independent
In this study, a comprehensive list of genes involved in generating DU-145 cells (data not shown).
and regulating the activities of BMPs was compiled. We tested the BMP-6 Induces p21/CIP Expression. The next set of experi-expression of these genes in DU-145 cells and analyzed how their ments were done to gain insight into how BMP-6 may control cell proliferation. Microarray data showed that BMP-6 treatment caused a strong up-regulation of p21/CIP mRNA within 6 hours. P21/CIP is a A 8282
